Daniel Brennan - Catalyst Pharmaceuticals Chief Commercial Officer
| CPRX Stock | USD 15.02 0.18 1.18% |
Executive
Mr. Daniel J. Brennan is Chief Commercial Officer of the company. He joined us in June 2018 as our Chief Commercial Officer. Mr. Brennan has over 20 years of experience in the pharmaceutical industry. Most recently, from October 2016 to May 2018, Mr. Brennan served as the Chief Operating Officer at Edge Therapeutics, where he was responsible for precommercialization activities of the companys lead product targeting rare neurological conditions. Prior to joining Edge Therapeutics, from November 2015 to August 2016, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics. Prior thereto from July 2009 to October 2015, Mr. Brennan held multiple leadership positions at Lundbeck U.S., including serving as Vice President and Group General Manager of Lundbecks U.S. Neurology Business Unit and Business Development group. Throughout his time in these positions, Lundbecks U.S. Neurology group launched four specialty orphan products. Prior to Lundbeck, Mr. Brennan was at Abbott Laboratories, where he served as Divisional Vice President and General Management of the Acute Care Hospital Business Unit. Previously, from 1997 to 2007, Mr. Brennan served in various sales, marketing and new product development roles with Eli Lilly and Company since 2018.
| Age | 50 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 355 Alhambra Circle, Coral Gables, FL, United States, 33134 |
| Phone | 305 420 3200 |
| Web | https://www.catalystpharma.com |
Daniel Brennan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Brennan against Catalyst Pharmaceuticals stock is an integral part of due diligence when investing in Catalyst Pharmaceuticals. Daniel Brennan insider activity provides valuable insight into whether Catalyst Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Catalyst Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalyst Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Brennan over two months ago Disposition of 1644 shares by Daniel Brennan of Boston Scientific at 65.82 subject to Rule 16b-3 |
Catalyst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1283 % which means that it generated a profit of $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2075 %, meaning that it created $0.2075 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| James Roach | Pulmatrix | N/A | |
| Carol MBA | Jaguar Animal Health | 60 | |
| David JD | Pulmatrix | 66 | |
| John JD | Adial Pharmaceuticals | N/A | |
| Serge Martinod | Jaguar Animal Health | 57 | |
| Brian Groch | Acasti Pharma | N/A | |
| Bankole Johnson | Adial Pharmaceuticals | 58 | |
| Robert CPA | Acasti Pharma | 52 | |
| David Hava | Pulmatrix | 40 | |
| Philippe Brianceau | Jaguar Animal Health | N/A | |
| Karen Brunke | Jaguar Animal Health | 71 | |
| Roger Waltzman | Jaguar Animal Health | N/A | |
| Peter Hodge | Jaguar Animal Health | N/A | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 |
Catalyst Pharmaceuticals Leadership Team
Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pete Sr, Vice Sales | ||
| Mary Coleman, VP Relations | ||
| Donald Denkhaus, Director | ||
| Gary MD, Chief Officer | ||
| Jeffrey Carmen, Executive Officer | ||
| Charles OKeeffe, Lead Independent Director | ||
| Bernardino Mosquera, Vice President - Clinical Operations | ||
| Alicia Grande, CFO, Vice President Treasurer | ||
| David Tierney, Independent Director | ||
| Preethi Sundaram, Chief Officer | ||
| Daniel Brennan, Chief Commercial Officer | ||
| Philip Coelho, Independent Director | ||
| Richard Daly, Interim Chief Commercial Officer, Director and Member of Nominating and Corporate Governance Committee | ||
| Philip Schwartz, Co Sec | ||
| CMA CPA, VP, Officer | ||
| Richard MBA, CEO President | ||
| Stanley MD, Senior Discovery | ||
| Michael CPA, Executive CFO | ||
| Gary Ingenito, Chief Medical Officer | ||
| David Connolly, IR Contact Officer | ||
| Douglas Winship, Vice President - Regulatory Operations | ||
| Patrick McEnany, Co-Founder, Chairman, CEO and Pres | ||
| Steven Miller, COO and Chief Scientific Officer | ||
| Brian Elsbernd, Chief Compliance Officer, Chief Legal Officer | ||
| David Caponera, Vice President - Patient Advocacy & Reimbursement | ||
| David Muth, Chief Commercial Officer and Executive VP | ||
| Brian JD, Chief Officer |
Catalyst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 1.66 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Shares Owned By Insiders | 6.21 % | ||||
| Shares Owned By Institutions | 73.55 % | ||||
| Number Of Shares Shorted | 6.27 M | ||||
| Price To Earning | 23.62 X |
Pair Trading with Catalyst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Catalyst Stock
| 0.78 | VKTX | Viking Therapeutics | PairCorr |
Moving against Catalyst Stock
| 0.78 | OVID | Ovid Therapeutics Financial Report 3rd of May 2024 | PairCorr |
| 0.64 | ORGO | Organogenesis Holdings Earnings Call This Week | PairCorr |
| 0.51 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.47 | GNFT | Genfit | PairCorr |
| 0.44 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.